XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) has announced the appointment of Wolfgang Probst as its chief operations officer and the addition of Manfred Buchberger as head of corporate development at XP Diagnostics GmbH, the company’s wholly-owned German subsidiary.
With European CE-IVD approval announced last month for the company's lead diagnostic product Covid-ID Lab, XPhyto said it continues to enhance its commercial team as it anticipates near-term distribution and sales.
In a statement, the company said COO Probst is an experienced management and finance consultant with expertise in mergers and acquisitions, corporate re-organizations, and divestitures. He has a proven track record of leadership, strategic planning, and organizational restructuring, having guided multiple start-ups from inception to financial success.
READ: XPhyto Therapeutics announces EU approval for coronavirus test
Probst also was responsible for successfully structuring XPhyto's European operations and establishing associated partnerships and collaborations, both commercial and academic. He will be responsible for managing the company's global operations and will remain a director of XPhyto and the managing director of XP Diagnostics.
The company said Buchberger is a global leader in the medical diagnostics industry. For almost a decade, he was the CEO and a member of the Global Management Board of a major European medical diagnostics and analytics company with annual revenues of over €600 million.
His addition brings decades of diagnostics industry experience focused on international business development, sales, marketing, and product management. Buchberger has successfully created, implemented, and managed business growth strategies across Europe, North and South America, the Middle East, and Asia, including the successful launch of new medical diagnostic products.
XPhyto noted that Probst and Buchberger will be responsible for executing the global product launch and business development of Covid-ID Lab, a rapid 25-minute point-of-care PCR test for COVID-19 that won EU approval on March 18.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham